Switch theme
Sign up to access all valuation multiples
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
2015
315
LTM Revenue $512M
LTM EBITDA $7.9M
$1.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Kiniksa Pharmaceuticals has a last 12-month revenue (LTM) of $512M and a last 12-month EBITDA of $7.9M.
In the most recent fiscal year, Kiniksa Pharmaceuticals achieved revenue of $423M and an EBITDA of -$43.9M.
Kiniksa Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Kiniksa Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $512M | XXX | $423M | XXX | XXX | XXX |
| Gross Profit | $441M | XXX | $362M | XXX | XXX | XXX |
| Gross Margin | 86% | XXX | 86% | XXX | XXX | XXX |
| EBITDA | $7.9M | XXX | -$43.9M | XXX | XXX | XXX |
| EBITDA Margin | 2% | XXX | -10% | XXX | XXX | XXX |
| EBIT | $7.7M | XXX | -$45.6M | XXX | XXX | XXX |
| EBIT Margin | 1% | XXX | -11% | XXX | XXX | XXX |
| Net Profit | $5.3M | XXX | -$43.2M | XXX | XXX | XXX |
| Net Margin | 1% | XXX | -10% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, Kiniksa Pharmaceuticals's stock price is $27.
Kiniksa Pharmaceuticals has current market cap of $2.0B, and EV of $1.7B.
See Kiniksa Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.7B | $2.0B | XXX | XXX | XXX | XXX | $0.06 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, Kiniksa Pharmaceuticals has market cap of $2.0B and EV of $1.7B.
Kiniksa Pharmaceuticals's trades at 4.1x EV/Revenue multiple, and -39.4x EV/EBITDA.
Equity research analysts estimate Kiniksa Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Kiniksa Pharmaceuticals has a P/E ratio of 376.9x.
See valuation multiples for Kiniksa Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.0B | XXX | $2.0B | XXX | XXX | XXX |
| EV (current) | $1.7B | XXX | $1.7B | XXX | XXX | XXX |
| EV/Revenue | 3.4x | XXX | 4.1x | XXX | XXX | XXX |
| EV/EBITDA | 219.3x | XXX | -39.4x | XXX | XXX | XXX |
| EV/EBIT | 225.6x | XXX | -37.9x | XXX | XXX | XXX |
| EV/Gross Profit | 3.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | 376.9x | XXX | -46.1x | XXX | XXX | XXX |
| EV/FCF | 12.6x | XXX | 68.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialKiniksa Pharmaceuticals's last 12 month revenue growth is 29%
Kiniksa Pharmaceuticals's revenue per employee in the last FY averaged $1.3M, while opex per employee averaged $1.3M for the same period.
Kiniksa Pharmaceuticals's rule of 40 is 20% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Kiniksa Pharmaceuticals's rule of X is 73% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Kiniksa Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 29% | XXX | 30% | XXX | XXX | XXX |
| EBITDA Margin | 2% | XXX | -10% | XXX | XXX | XXX |
| EBITDA Growth | 924% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 20% | XXX | 18% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 73% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 26% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 96% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Kiniksa Pharmaceuticals acquired XXX companies to date.
Last acquisition by Kiniksa Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Kiniksa Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Kiniksa Pharmaceuticals founded? | Kiniksa Pharmaceuticals was founded in 2015. |
| Where is Kiniksa Pharmaceuticals headquartered? | Kiniksa Pharmaceuticals is headquartered in United States of America. |
| How many employees does Kiniksa Pharmaceuticals have? | As of today, Kiniksa Pharmaceuticals has 315 employees. |
| Who is the CEO of Kiniksa Pharmaceuticals? | Kiniksa Pharmaceuticals's CEO is Mr. Sanj K. Patel. |
| Is Kiniksa Pharmaceuticals publicy listed? | Yes, Kiniksa Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Kiniksa Pharmaceuticals? | Kiniksa Pharmaceuticals trades under KNSA ticker. |
| When did Kiniksa Pharmaceuticals go public? | Kiniksa Pharmaceuticals went public in 2018. |
| Who are competitors of Kiniksa Pharmaceuticals? | Similar companies to Kiniksa Pharmaceuticals include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Kiniksa Pharmaceuticals? | Kiniksa Pharmaceuticals's current market cap is $2.0B |
| What is the current revenue of Kiniksa Pharmaceuticals? | Kiniksa Pharmaceuticals's last 12 months revenue is $512M. |
| What is the current revenue growth of Kiniksa Pharmaceuticals? | Kiniksa Pharmaceuticals revenue growth (NTM/LTM) is 29%. |
| What is the current EV/Revenue multiple of Kiniksa Pharmaceuticals? | Current revenue multiple of Kiniksa Pharmaceuticals is 3.4x. |
| Is Kiniksa Pharmaceuticals profitable? | Yes, Kiniksa Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Kiniksa Pharmaceuticals? | Kiniksa Pharmaceuticals's last 12 months EBITDA is $7.9M. |
| What is Kiniksa Pharmaceuticals's EBITDA margin? | Kiniksa Pharmaceuticals's last 12 months EBITDA margin is 2%. |
| What is the current EV/EBITDA multiple of Kiniksa Pharmaceuticals? | Current EBITDA multiple of Kiniksa Pharmaceuticals is 219.3x. |
| What is the current FCF of Kiniksa Pharmaceuticals? | Kiniksa Pharmaceuticals's last 12 months FCF is $138M. |
| What is Kiniksa Pharmaceuticals's FCF margin? | Kiniksa Pharmaceuticals's last 12 months FCF margin is 27%. |
| What is the current EV/FCF multiple of Kiniksa Pharmaceuticals? | Current FCF multiple of Kiniksa Pharmaceuticals is 12.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
